secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001193125-25-169947
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%
-----------------------------------------------------------------------

- Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.
- SUBLOCADE net revenue $209M (+9% YoY, +19% vs Q1'25); U.S. SUBLOCADE $195M (+9% YoY).
- FY 2025 guidance raised: net revenue $1.03B-$1.08B (prior $955M-$1.025B); adjusted EBITDA $275M-$300M (prior $220M-$260M).
- Adjusted EBITDA Q2 $88M vs $93M Q2'24; cash and investments $538M at Q2 end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/0001193125-25-169947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/d908304d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-169947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer